RDEA3170 PK/PD Study

Study identifier:RDEA3170-112

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Will Be Recruiting

Official Title

A Phase 1, Randomized, Open-Label Study in Healthy Adult Male Subjects to Assess the Pharmacokinetics and Pharmacodynamics of RDEA3170

Medical condition

Gout

Phase

Phase 1

Healthy volunteers

Yes

Study drug

RDEA3170 4.5 mg, RDEA3170 6 mg, RDEA3170 12 mg

Sex

Male

Estimated Enrollment

40

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 01 Nov 2015
Estimated Primary Completion Date: 01 Dec 2015
Estimated Study Completion Date: 01 Feb 2016

Study design

Allocation: Randomized
Endpoint Classification: Pharmacokinetics/dynamics
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Nov 2015 by Ardea Biosciences, Inc.

Sponsors

Ardea Biosciences, Inc.

Collaborators

-

Inclusion and exclusion criteria